Hi, this is Theresa Agnew, CEO of BioGaia. We are here to present our Q4 results. So first off, our financial highlights.
We had strong organic growth for the quarter of 32%. We had an EBIT Margin of 27% and overall Free Cashflow at 77 MSEK.
In terms of an overall summary for the year, we hit 1.5 billion SEK, an increase of 14% in organic growth compared to last year, and overall 8% growth adjusted for currency effects in the fourth quarter. As I said, we had 32% organic growth and 21% excluding currency effects. We did experience some order variability in the fourth quarter. As is typical across some of our quarters, and that was approximately 35 million SEK. Our overall operating profit for the quarter was 121 million SEK, which is an increase of 17%.
And our EBIT margin, as I said, was 27% for the quarter.
In terms of our strategy, we have three strategic pillars. Our first is what we call Grow the Core. And these are our core health areas, of which gut health, colic is a part of that. For infants, gut health, oral health, and immune health are our three core health areas that we focus on through our marketing and commercial excellence.
Our second strategic area is what we call expansion through direct markets. So I'll talk about this a little bit in terms of how we have been expanding our business through new direct markets in 2025. And then our third strategic pillar is what we call breakthrough innovation. So think about this as market creation.
Opportunities for probiotics where they are not used regularly. And the foundations that underpin our strategy are, of course, our people and culture. Investing for profitable growth, digital as an enabler of our business in terms of how we go to market with our omnichannel approach, as well as digitizing our business internally for more productivity and efficiency. One of our foundations, which has been a foundation for many years, is driven by science.
It's a key differentiator of who we are as a brand and in our products.
And then finally, sustainable solutions, where we're focused on sustainability in multiple areas, packaging, raw materials, and so forth. How did we deliver on our strategy? In terms of our first area, Grow the Core. We're driving growth, as you saw in both the pediatric and adult segments for the quarter as well as for the year. We're investing in marketing and selling activities to drive very strong growth in the direct markets, and we are growing ahead in our direct markets. So strong double digit growth versus our partner markets.
We continue to roll out new products. So we launched a product called BioGaia Gastrus Pure Action in the fourth quarter of 2024. And so in 2025, we continued to roll that out across a number of countries. And I'm very happy to report that in Q4, this product really set a record. It is the third highest growth contributor in terms of million SEK to our business. So it's doing extremely well in the markets where we've launched.
And then finally in Q3, we launched Prodentis Fresh Breath.
We launched that in the US market and have also been rolling that out in Q4 and will continue to do so in 2026. So these two product launches have been very beneficial for us in terms of driving our growth, and we'll continue to roll them out in more markets in 2026.
In terms of our second strategic area, expansion through direct markets, our direct market sales now in Q4 represent 40% of our sales and as I said, are growing ahead of our partner markets. So this has been a change over the last two years; our sales used to be around 30%. Now it's 40% driven by our direct markets. We launched in France in 2025 and also the Netherlands.
So those two markets are doing well.
France had strong Q4 sales with record sales. Australia, we had launched in 2024, and that market in particular is doing very well for us. Our BioGaia Protectis drops are now number one in the market in Australia, whereas they previously were not with our previous partner. And in 2025, we had record sales in our US market, 316 million SEK, which represents 30% organic growth. So very strong performance by our US market as well as our Canadian market.
Also strong double-digit growth in terms of breakthrough innovation.
In 2025, we established a new subsidiary called BioGaia New Sciences with a strong focus on skin health. We have our probiotic ointment that we launched and is now rolling out to more markets in 2025, and it is also performing well where it was introduced. So this is an overview of how we've delivered on our strategy in Q4 as well as in 2025.
In terms of our product launches, as you can see, we had a lot of product launches in Q4.
So this lists all the different countries where we have launched different products, whether it be Protectis drops, which is one of our immune health products, or ProDentis Fresh Breath lozenges, as I mentioned, Gastrus products or ProDentis products. So various new launches across markets in Q4. And as you see here, we've highlighted the markets where we rolled out Gastrus Pure Action, which I mentioned, in Q4. Some of the key events that we have talked about in the quarter.
In October, we announced a study on a new patented strain, which is called L. reuteri BG-R46, and that was published in a journal called Beneficial Microbes. Also in October, we talked about a study on a new bacteria that actually produces serotonin. So this is a first for bacteria. So more to come on this; this is a preclinical discovery. So we'll be doing more work on this in the future. And as you know, serotonin dramatically affects the brain in terms of mood and overall well-being of mental health.
And then, just recently in February, we announced that our fourth quarter results exceeded our market expectations. And the board is proposing an ordinary dividend, according to our policy, and also an extra dividend for a total dividend of four SEK per share. And overall, when you look at the business for Q4, as I said, we had 32% overall organic growth in the quarter, with Pediatrics growing by 34% and Adult Health by 27%. So pediatrics represents about 75% of our overall revenue. And in the quarter we saw some significant increases for Protectis drops in China as well as France. And also in the quarter for adults. We saw some significant increases in Gastrus as well as Prodentis, mainly in the USA.
And in the chart.
You can see our quarterly variations over the last two years, so you can see the various fluctuations. Sometimes we'll have more orders from partners in one quarter, less orders from partners in another quarter. And in terms of our sales per segment, I mentioned Pediatrics and Adult Health for the quarter. But overall for the year, we had organic growth in Pediatrics of 11% and 22% in Adult Health. So both of these areas are growing very well overall for the quarter as well as for the year in 2025. In terms of our regions for Europe, Middle East, Africa, in the quarter, we grew 34%. And this is organic growth. And in terms of the year, we grew 1% in Europe, Middle East, Africa.
A couple comments here. For the quarter, we saw some increases in sales in France and Eastern Europe as well as in Italy.
But also overall for the year, we took our business direct starting in April. So in Q1, we had much lower orders from our partner.
And also, we had a period of time where our partner sold through their inventory. So then it takes a while for our sales in the direct market to build. So that's also what impacted the overall year for EMEA as well as Germany. So we're now taking Germany direct. We've now launched that in Q1 Germany and Austria.
So same thing.
In 2025, we saw our distributor partner have fewer orders, so we had less overall sales and then we started to see that pick up. So we will see the continuing decline of those orders from our partner in the beginning of this year, 2026, and then start to see the sales grow for Germany in the second half of 2026.
So for Asia Pacific, organic growth for the quarter was 46%, and for the full year, it was 19%, with very strong organic growth noted in China and the Philippines during the quarter. We also had some quarterly variations for China in terms of orders for Q4. So, overall, Asia PAC performed extremely well in terms of overall growth, with strong performance, as I said, in China, the Philippines, and Indonesia for the year; for the Americas, for the quarter, we saw 20% organic growth and overall for the year, 22% organic growth.
So in the Americas, as I said, the US is a standout market for us in terms of growth.
So 30% overall organic growth for the year. In addition, we saw strong growth in Guatemala as well. And as we've discussed previously, especially in the US, we had increased our marketing investments to drive our overall brand awareness and equity and expand our market share. And we successfully did that in 2025. So now I will turn it over to Alex to go through the financials in more detail.